Long-term Outcomes and Prognostic Factors for Locally-Advanced Pancreatic Cancer Patients Treated with Intraoperative Radiation Therapy

S. Cai,T. S. Hong,S. I. Goldberg,C. Fernandez-del Castillo,S. P. Thayer,C. R. Ferrone,D. P. Ryan,C. G. Willett,A. L. Warshaw,J. Y. Wo
DOI: https://doi.org/10.1016/j.ijrobp.2013.06.797
2013-01-01
Abstract:The aim of this study was to evaluate long-term outcomes, IORT-related toxicity, and prognostic factors for overall survival (OS) for unresectable locally advanced pancreatic cancer (LAPC) patients who received intraoperative radiation therapy (IORT) as part of their treatment between 1978 and 2010. Medical records were retrospectively reviewed for 194 consecutive LAPC patients treated with IORT at MGH between 1978 and 2010. OS was calculated using the Kaplan-Meier method. Prognostic factors were evaluated at the univariate level by the log-rank test and at the multivariate level by the Cox proportional hazards model. Rates and patterns of disease progression and treatment toxicity were documented. Median OS was 12.0 months, with actuarial 1-, 2-, and 3-year survival rates of 49%, 16%, and 6%, respectively. Six patients lived past 5 years. The acute IORT-related postoperative grade 3 complication rate and late complication rate were 21% and 14%, respectively. Among 183 patients with available post-IORT disease status follow-up, actuarial 2-year locoregional recurrence-free survival and distant metastasis-free survival rates were 41% and 28%, respectively. On multivariate prognostic factor analysis, IORT applicator diameter ≤ 8 cm (HR = 0.51; p = 0.009), Charlson age-comorbidity index (CACI) ≤ 3 (HR = 0.47; p = 0.001), and receipt of chemotherapy (HR = 0.46; p < 0.001) were associated with improved OS. Median OS for patients with all 3 positive prognostic factors was 21.2 months. Among 57 patients who received chemotherapy as part of their treatment, median OS was 17.6 months, with actuarial 1-, 2-, and 3-year survival rates of 71%, 33%, and 15%, respectively. Multivariate analysis yielded CACI ≤ 3 (HR = 0.26; p = 0.002) but not IORT applicator diameter as a significant prognostic factor for OS. Well-selected LAPC patients can achieve good long-term survival outcomes with a treatment regimen that incorporates chemotherapy and IORT.
What problem does this paper attempt to address?